SACRAMENTO, Calif., April 22, 2025 /PRNewswire/ -- Health Net, one of California's most experienced Medi-Cal managed care health plans and a company of Centene Corporation (NYSE: CNC), today announced a $3.5 million grant to MLK Community Medical Group to help sustain and expand vital healthcare services in Los Angeles by supporting the hiring of key clinicians, including those providing perinatal and behavioral health care.
"Clinicians are the backbone of our healthcare system. Their dedication keeps care accessible and communities healthier," said Mireya Fajardo, vice president, Medi-Cal regional lead at Health Net. "When we invest in them, we expand access and strengthen care delivery in places that need it most."
Specifically, the grant will fund the addition of two primary care physicians, one obstetrician-gynecologist, one bilingual psychologist and two certified nurse midwives through the end of 2027.
Rising demand for healthcare services and a shortage of clinical professionals have made it increasingly difficult for patients to receive timely appointments and care. Supporting clinicians and expanding healthcare resources are key steps in addressing these gaps and ensuring that all individuals have access to the services they need.
"This generous grant from Health Net will help bolster our clinician workforce, ensuring that more patients receive the care they need, when they need it," said Dyan Sublett, president at MLK Community Health Foundation. "By investing in our healthcare providers, Health Net is strengthening the foundation of our community's health and well-being."
This grant builds on Health Net's ongoing commitment to workforce development. The company recently committed over $9 million to grow California's physician pipeline, from early education through medical school to practice, ensuring care continues for years to come.
"Health Net's support for one of our South LA community assets is a welcomed investment and a testament to the quality health care services MLK Community Medical Group provides to countless residents" said Los Angeles County Supervisor Holly J. Mitchell.
To learn more about Health Net's local commitments, visit www.bridgingthedivideca.com.
About Health Net
Founded in California more than 45 years ago, Health Net, LLC ("Health Net"), a company of Centene Corporation, believes that every person deserves a safety net for their health, regardless of age, income, employment status or current state of health. Today, we provide health plans for individuals, families, businesses of every size and people who qualify for Medi-Cal or Medicare. With more than 117,000 of our network providers, Health Net serves more than three million members across the state. We also offer access to substance abuse programs, behavioral health services and managed healthcare products related to prescription drugs. We make these health plans and services available through Health Net and its subsidiaries: Health Net of California, Inc., Health Net Life Insurance Company and Health Net Community Solutions, Inc. These entities are wholly owned subsidiaries of Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to transforming the health of the communities we serve, one person at a time. Health Net and Centene Corporation employ more than 5,700 people in California who work at one of five regional Talent Hub offices. For more information, visit www.HealthNet.com.
Last Trade: | US$57.44 |
Daily Change: | -4.14 -6.72 |
Daily Volume: | 8,408,467 |
Market Cap: | US$29.000B |
April 25, 2025 February 24, 2025 February 04, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load